サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
市場調査レポート
商品コード
1565035

グライコミクス/糖鎖生物学の世界市場

Glycomics / Glycobiology

出版日
ページ情報
英文 249 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.06円
グライコミクス/糖鎖生物学の世界市場
出版日: 2024年10月04日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 249 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

グライコミクス/糖鎖生物学の世界市場は2030年までに64億米ドルに到達

2023年に21億米ドルと推定されたグライコミクス/糖鎖生物学の世界市場は、分析期間2023-2030年にCAGR 16.9%で成長し、2030年には64億米ドルに達すると予測されます。本レポートで分析したセグメントの1つである酵素は、CAGR17.8%を記録し、分析期間終了時には29億米ドルに達すると予測されます。キット＆試薬セグメントの成長率は、分析期間中CAGR16.8％と推定されます。

米国市場は推定5億9,290万米ドル、中国はCAGR16.0％で成長予測

米国のグライコミクス/糖鎖生物学市場は、2023年に5億9,290万米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに9億6,640万米ドルの市場規模に達すると予測され、分析期間2023-2030年のCAGRは16.0%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ14.9%と14.3%と予測されています。欧州では、ドイツがCAGR約12.2%で成長すると予測されています。

世界のグライコミクス/糖鎖生物学市場- 主要動向と促進要因のまとめ

グライコミクス／糖鎖生物学がバイオテクノロジーと医学の主要分野として台頭しているのはなぜか？

糖鎖生物学とも呼ばれるグライコミクスは、複雑な生物学的プロセスを理解し、治療法を進歩させる上で重要な役割を果たすため、バイオテクノロジーと医学において不可欠な分野になりつつあります。しかし、なぜ今日、グライコミクスがこれほど重要なのでしょうか？糖鎖生物学とは、タンパク質や脂質に結合し、細胞シグナル伝達、免疫応答、疾患の進行など、多種多様な生物学的機能に関与する複合糖質である糖鎖を包括的に研究する学問です。糖鎖生物学は、これらの糖分子が細胞コミュニケーション、疾病メカニズム、および新しい診断法や治療法の開発にどのように影響するかに焦点を当てています。

糖鎖は、がん、自己免疫疾患、感染症などの疾患の進行に重要な役割を果たしているため、糖鎖生物学の研究は、人間の健康にとって広範な意味を持っています。糖鎖の構造と機能を解読することにより、研究者は病気を早期に診断し、より的を絞った治療法を開発し、より効果的なワクチンを開発する新しい方法を発見しています。さらにグリコミクスは、薬物相互作用の理解や生物製剤の設計に不可欠であり、これらは精密医療において不可欠なツールとなりつつあります。個別化ヘルスケアの重要性が高まるにつれ、グリコミクスは、身体の機能を分子レベルで解明する新たな洞察の解明に役立ち、診断学、治療学、ワクチン開発のイノベーションを促進しています。

技術の進歩はグリコミクスの研究と応用をどのように加速しているか？

技術の進歩は、糖鎖の複雑性を解読し、生物学的システムにおける多様な機能を明らかにすることを可能にし、グリコミクス研究を推進する上で極めて重要な役割を果たしています。重要な進歩の一つは、質量分析（MS）や液体クロマトグラフィー（LC）などのハイスループット糖鎖分析技術の開発であり、これにより糖鎖構造の迅速な同定と特性解析が可能になった。これらのツールにより、研究者は生物または組織内の糖鎖全体であるグリカン（glycome）を、かつてないほど迅速かつ高精度でマッピングできるようになった。この能力は、糖鎖が組織、個体、病態によってどのように異なるかを理解する上で極めて重要であり、より個別化された治療への道を開くものです。

もう一つの重要な技術的進歩は、バイオインフォマティクス・ツールのグリコミクス研究への応用です。多数の枝分かれと多様な構成を持つ糖鎖構造の複雑さには、解析と解釈のための高度な計算手法が必要です。機械学習と人工知能（AI）の進歩により、糖鎖構造とタンパク質や脂質との相互作用を予測できるアルゴリズムの開発が可能になりつつあります。これらのバイオインフォマティクスツールは、研究者が疾患の糖鎖バイオマーカーを特定し、糖鎖ベースの治療薬を開発し、糖鎖の変化が疾患の進行にどのように関与しているかを明らかにするのに役立ちます。AI主導の分析により、科学者は膨大な量の糖鎖データをふるいにかけ、パターンや潜在的な治療標的をより効率的に特定することができます。

合成糖鎖生物学の進歩は、合成糖鎖の設計と製造を可能にすることで、この分野にも変革をもたらしつつあります。これらの合成糖鎖は天然に存在する分子を模倣しており、ワクチン開発、創薬、治療研究に利用されています。例えば、病原体がヒト細胞とどのように相互作用するかを研究したり、強力な免疫反応を引き起こすワクチンを開発するために、研究者は特定の糖鎖構造を作り出すことができます。この能力は、糖鎖が免疫回避において重要な役割を果たすインフルエンザやコロナウイルスのような複雑なウイルスに対するワクチンを開発する上で特に重要です。さらに、合成糖鎖は、がん細胞上の特定の受容体を標的としたり、免疫応答を調節したりする糖鎖ベースの薬剤の開発に利用され、精密医療への新たな道を開いています。

もう一つの進歩分野は、クライオ電子顕微鏡（クライオEM）や糖鎖アレイ技術などの高度なイメージング技術の利用です。これらのツールは、糖鎖が他の生体分子とどのように相互作用するかを分子レベルで可視化することを可能にします。これは、細胞シグナル伝達、病原体認識、免疫系機能などのプロセスにおける糖鎖の役割を理解する上で極めて重要です。例えば糖鎖アレイは、タンパク質との糖鎖相互作用のハイスループットスクリーニングを可能にし、がんや神経変性疾患などの疾患に対する潜在的な創薬ターゲットやバイオマーカーを明らかにすることができます。これらのイメージングおよびスクリーニング技術は、健康および疾患における糖鎖のダイナミックな役割について、より深い洞察をもたらしています。

疾患メカニズムの解明、診断薬の開発、治療法の進歩にグリコミクスが不可欠なのはなぜか？

糖鎖は生物学的プロセスおよび疾患の進行を制御する上で基本的な役割を果たすため、グリコミクスは疾患メカニズムの理解、診断法の開発、および治療法の進歩に不可欠です。糖鎖は、タンパク質のフォールディングや安定性から免疫系の活性化や細胞間コミュニケーションに至るまで、細胞機能のほぼすべての側面に関与しています。糖鎖構造の変化はしばしば疾患状態と関連しており、グライコミクスはバイオマーカーを同定し、疾患メカニズムを分子レベルで理解するための貴重なツールとなっています。

グリコミクスの医学への最も重要な貢献の一つは、疾患の早期発見のためのバイオマーカーを発見する能力です。グリコシル化（糖鎖がタンパク質や脂質に結合する過程）の変化は、がん、糖尿病、感染症などの疾患で頻繁に観察されます。例えば、異常な糖鎖パターンはがん細胞の特徴であり、腫瘍の増殖、転移、免疫回避を促進する可能性があります。これらの変化した糖鎖シグネチャーを同定することで、研究者はより高感度で特異的な診断テストを開発することができます。糖鎖に基づくバイオマーカーは、疾患の早期発見に革命をもたらす可能性を秘めており、臨床医は、がん、肝臓疾患、神経変性疾患などの疾患を、治療が有効である可能性が高い早期の段階で診断できるようになります。

治療においては、グライコミクスはより的を絞った効果的な治療法の開発を可能にしています。糖鎖構造は、特に異常なグリコシル化が関与する疾患において、薬剤の標的となり得る。例えば、ある種のがんは、その表面タンパク質に特異的な糖鎖パターンを示し、グリコミクス研究は、これらの異常な糖鎖を特異的に標的とする治療法の開発につながっています。このような糖鎖を標的とする治療は、健康な組織へのダメージを最小限に抑えつつ、病変細胞に焦点を当てるという、より精密な治療アプローチを提供します。グリコミックスはまた、病原体やがん細胞に対する免疫認識を高める糖鎖ベースのワクチンの設計にも貢献しています。糖鎖は、免疫系が外敵を識別する際に重要な役割を果たしており、合成糖鎖を組み込んだワクチンは、より強力で特異的な免疫反応を引き起こすことができます。

糖鎖工学は、モノクローナル抗体、遺伝子治療、細胞ベースの治療を含む、成長中の治療薬である生物製剤の開発にも不可欠です。治療用抗体のような多くの生物製剤は、その安定性、有効性、安全性においてグリコシル化に依存しています。医薬品製造中のグリコシル化パターンを理解し制御することは、生物製剤が正しく機能し、患者にとって安全であることを保証するために極めて重要です。Glycomics社は、製造中のグリコシル化をモニターし最適化するために必要なツールを提供し、製薬会社がより効果的で一貫性のある生物学的製剤を開発するのを支援します。

治療薬や診断薬に加え、グリコミックスは個別化医療の進展においても極めて重要な役割を果たしています。糖鎖パターンは遺伝的および環境的要因に基づいて個人間で異なる可能性があるため、これらの変化を理解することで、患者固有の糖鎖プロファイルに合わせた個別化治療の開発が可能になります。このことは、腫瘍がしばしば特異的な糖鎖パターンを示すがんにおいて特に重要であり、個別化治療の標的とすることができます。グライコミクスの分野が進化を続けるにつれ、個々の患者の分子プロファイルに合わせたより効果的な治療を可能にし、精密医療の未来を形作る上でますます重要な役割を果たすようになると思われます。

グリコミクス／糖鎖生物学市場の成長を促す要因とは？

グライコミクス/糖鎖生物学市場の急成長には、個別化医療に対する需要の高まり、医薬品開発の進展、複雑な疾患の有病率の増加、糖鎖分析の技術革新など、いくつかの主な要因があります。まず、個別化医療の推進がグリコミクスの市場促進要因となっています。ヘルスケアが画一的なアプローチからより個別化された治療へとシフトする中、グライコミクスは治療の個別化に利用できる固有の糖鎖プロファイルを同定するツールを提供します。これは、がん細胞がしばしば特異的な糖鎖変化を示す腫瘍学において特に重要であり、より効果的な治療の標的とすることができます。疾患の早期発見や個別化治療戦略のために糖鎖バイオマーカーを利用できることが、研究および臨床の場におけるグライコミクス技術の需要を高めています。

第二に、医薬品開発、特に生物製剤とモノクローナル抗体の分野における進歩が、グライコミクス市場の成長に寄与しています。生物学的製剤の多くは、その活性、安定性、安全性において糖鎖修飾に依存しており、薬剤製造時にこれらの糖鎖構造を制御することは、効果的な治療法を生み出すために不可欠です。製薬会社は、生物学的製剤のグリコシル化を最適化し、これらの治療が有効性と安全性の最高基準を満たすようにするため、グリコミクスツールや技術への投資を増やしています。医薬品開発におけるこのような精密さの要求は、製薬業界におけるグリコミクスの採用を促進しています。

第三に、がん、自己免疫疾患、神経変性疾患などの複雑な疾患の有病率の増加により、高度な診断・治療ソリューションの必要性が高まっています。グライコミクスは、糖鎖付加の変化が疾患の進行にどのように関与しているかについての洞察を提供することで、このニーズに対応するユニークな立場にあります。例えば、糖鎖に基づくバイオマーカーはがんの早期発見のために開発されており、糖鎖を標的とした治療法は自己免疫疾患や感染症の新規治療法として研究されています。こうした疾患の世界の負担が増加し続ける中、グライコミクスに基づくソリューションの需要は大きく伸びると予想されます。

糖鎖分析の技術革新もグライコミクス市場の拡大を後押ししています。質量分析、糖鎖アレイ、バイオインフォマティクスツールの進歩により、研究者はより高速、高精度、高分解能で糖鎖を解析できるようになっています。これらの技術により、科学者はグライコームのマッピング、疾患特異的な糖鎖変化の同定、新しい糖鎖ベースの治療法の開発を容易に行えるようになっています。ハイスループット糖鎖解析ツールの利用可能性が高まるにつれ、研究が加速し、診断、治療、ワクチン開発などの分野におけるグライコミクスの商業的可能性が拡大しています。

さらに、グライコミクス研究への資金提供の増加や専門的なグライコミクス研究センターの設立が、市場の成長に寄与しています。政府、学術機関、非公開会社は、ヘルスケアを変革する可能性があることから、グリコミクス研究に多額の投資を行っています。学術界、産業界、ヘルスケアプロバイダー間の協力的な取り組みにより、臨床におけるグリコミクスの応用が進んでおり、グリコミクスツールおよび技術の需要をさらに促進しています。

結論として、グライコミクス/糖鎖生物学市場の成長は、個別化医療に対する需要の増加、医薬品開発の進歩、複雑な疾患の有病率の増加、および糖鎖解析における技術革新によって牽引されています。グライコミクスが健康と疾患における糖鎖の役割についてより深い洞察を提供し続けるにつれて、幅広い医療および産業用途における診断、治療、精密医療の未来を形作る上で重要な役割を果たすようになるでしょう。

調査対象企業の例（全152件）

  • Agilent Technologies, Inc.
  • Bruker Corporation
  • Danaher Corporation
  • Merck KgaA
  • New England Biolabs, Inc.
  • Prozyme, Inc.
  • Shimadzu Corporation
  • Takara Bio, Inc.
  • Thermo Fisher Scientific, Inc.
  • Waters Corporation

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • その他欧州
  • アジア太平洋
  • その他の地域

第4章 競合

目次
Product Code: MCP12203

Global Glycomics / Glycobiology Market to Reach US$6.4 Billion by 2030

The global market for Glycomics / Glycobiology estimated at US$2.1 Billion in the year 2023, is expected to reach US$6.4 Billion by 2030, growing at a CAGR of 16.9% over the analysis period 2023-2030. Enzymes, one of the segments analyzed in the report, is expected to record a 17.8% CAGR and reach US$2.9 Billion by the end of the analysis period. Growth in the Kits & Reagents segment is estimated at 16.8% CAGR over the analysis period.

The U.S. Market is Estimated at US$592.9 Million While China is Forecast to Grow at 16.0% CAGR

The Glycomics / Glycobiology market in the U.S. is estimated at US$592.9 Million in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$966.4 Million by the year 2030 trailing a CAGR of 16.0% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 14.9% and 14.3% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 12.2% CAGR.

Global Glycomics / Glycobiology Market - Key Trends and Drivers Summarized

Why Is Glycomics/Glycobiology Emerging as a Key Field in Biotechnology and Medicine?

Glycomics, also referred to as glycobiology, is becoming an essential field in biotechnology and medicine due to its critical role in understanding complex biological processes and advancing therapeutic solutions. But why is glycomics so vital today? Glycomics is the comprehensive study of glycans—complex carbohydrates that attach to proteins and lipids and are involved in a wide variety of biological functions, including cell signaling, immune response, and disease progression. Glycobiology focuses on how these sugar molecules influence cellular communication, disease mechanisms, and the development of new diagnostics and treatments.

The study of glycomics has far-reaching implications for human health, as glycans play a crucial role in the progression of diseases such as cancer, autoimmune disorders, and infections. By decoding the structure and function of glycans, researchers are uncovering new ways to diagnose diseases earlier, develop more targeted therapies, and create more effective vaccines. Moreover, glycomics is critical for understanding drug interactions and designing biologics, which are rapidly becoming essential tools in precision medicine. As the importance of personalized healthcare grows, glycomics is helping to unlock new insights into how the body functions at a molecular level, driving innovation in diagnostics, therapeutics, and vaccine development.

How Are Technological Advancements Accelerating Research and Applications in Glycomics?

Technological advancements are playing a pivotal role in advancing glycomics research, making it possible to decode the complexities of glycans and uncover their diverse functions in biological systems. One significant advancement is the development of high-throughput glycan analysis techniques, such as mass spectrometry (MS) and liquid chromatography (LC), which allow for the rapid identification and characterization of glycan structures. These tools enable researchers to map the glycome—the entire set of glycans in an organism or tissue—faster and with greater accuracy than ever before. This capability is crucial for understanding how glycans differ across tissues, individuals, or disease states, paving the way for more personalized medical treatments.

Another key technological advancement is the application of bioinformatics tools to glycomics research. The complexity of glycan structures, with their numerous branches and diverse configurations, requires sophisticated computational methods for analysis and interpretation. Advances in machine learning and artificial intelligence (AI) are enabling the development of algorithms that can predict glycan structures and their interactions with proteins and lipids. These bioinformatics tools help researchers identify glycan biomarkers for diseases, develop glycan-based therapeutics, and uncover how glycan alterations contribute to disease progression. With AI-driven analytics, scientists can sift through vast amounts of glycomic data to identify patterns and potential therapeutic targets more efficiently.

Advances in synthetic glycobiology are also transforming the field by enabling the design and production of synthetic glycans. These synthetic glycans mimic naturally occurring molecules and are used in vaccine development, drug discovery, and therapeutic research. For instance, researchers can create specific glycan structures to study how pathogens interact with human cells or to develop vaccines that elicit strong immune responses. This capability is particularly important for developing vaccines for complex viruses like influenza and coronaviruses, where glycans play a key role in immune evasion. Additionally, synthetic glycans are being used in the development of glycan-based drugs that target specific receptors on cancer cells or modulate immune responses, opening new avenues for precision medicine.

Another area of advancement is the use of advanced imaging techniques, such as cryo-electron microscopy (cryo-EM) and glycan array technology. These tools allow scientists to visualize how glycans interact with other biomolecules at the molecular level. This is crucial for understanding the role of glycans in processes like cell signaling, pathogen recognition, and immune system function. Glycan arrays, for example, enable the high-throughput screening of glycan interactions with proteins, which can reveal potential drug targets or biomarkers for diseases like cancer and neurodegenerative disorders. These imaging and screening technologies are providing deeper insights into the dynamic role of glycans in health and disease.

Why Is Glycomics Critical for Understanding Disease Mechanisms, Developing Diagnostics, and Advancing Therapeutics?

Glycomics is critical for understanding disease mechanisms, developing diagnostics, and advancing therapeutics because glycans play a fundamental role in regulating biological processes and disease progression. Glycans are involved in nearly every aspect of cellular function, from protein folding and stability to immune system activation and cell-cell communication. Alterations in glycan structures are often associated with disease states, making glycomics an invaluable tool for identifying biomarkers and understanding disease mechanisms at a molecular level.

One of the most important contributions of glycomics to medicine is its ability to uncover biomarkers for early disease detection. Changes in glycosylation—the process by which glycans attach to proteins or lipids—are frequently observed in diseases like cancer, diabetes, and infectious diseases. For example, abnormal glycan patterns are a hallmark of cancer cells, where they can promote tumor growth, metastasis, and immune evasion. By identifying these altered glycan signatures, researchers can develop more sensitive and specific diagnostic tests. Glycan-based biomarkers hold the potential to revolutionize early disease detection, allowing clinicians to diagnose conditions like cancer, liver disease, and neurodegenerative disorders at earlier stages, when treatments are more likely to be effective.

In therapeutics, glycomics is enabling the development of more targeted and effective treatments. Glycan structures can serve as drug targets, particularly in diseases where abnormal glycosylation is involved. For instance, certain cancers exhibit unique glycan patterns on their surface proteins, and glycomics research is leading to the development of therapies that specifically target these aberrant glycans. These glycan-targeting therapies offer a more precise approach to treatment, minimizing damage to healthy tissues while focusing on the diseased cells. Glycomics is also contributing to the design of glycan-based vaccines that enhance immune recognition of pathogens or cancer cells. Glycans play a crucial role in how the immune system identifies foreign invaders, and vaccines that incorporate synthetic glycans can trigger stronger and more specific immune responses.

Glycomics is also essential for the development of biologics, a growing class of therapeutics that includes monoclonal antibodies, gene therapies, and cell-based treatments. Many biologics, such as therapeutic antibodies, rely on glycosylation for their stability, efficacy, and safety. Understanding and controlling glycosylation patterns during drug manufacturing is critical for ensuring that biologics function correctly and are safe for patients. Glycomics provides the tools needed to monitor and optimize glycosylation during production, helping pharmaceutical companies develop more effective and consistent biologic therapies.

In addition to therapeutics and diagnostics, glycomics is playing a pivotal role in advancing personalized medicine. Since glycan patterns can vary between individuals based on genetic and environmental factors, understanding these variations allows for the development of personalized treatments tailored to a patient’s specific glycan profile. This is particularly important in cancer, where tumors often exhibit unique glycosylation patterns that can be targeted with personalized therapies. As the field of glycomics continues to evolve, it will play an increasingly important role in shaping the future of precision medicine, enabling more effective treatments that are customized to individual patients’ molecular profiles.

What Factors Are Driving the Growth of the Glycomics/Glycobiology Market?

Several key factors are driving the rapid growth of the glycomics/glycobiology market, including the increasing demand for personalized medicine, advancements in drug development, the growing prevalence of complex diseases, and technological innovations in glycan analysis. First, the push toward personalized medicine is a major driver of the glycomics market. As healthcare shifts from a one-size-fits-all approach to more individualized treatments, glycomics offers the tools to identify unique glycan profiles that can be used to tailor therapies. This is particularly important in oncology, where cancer cells often exhibit specific glycan changes that can be targeted for more effective treatments. The ability to use glycan biomarkers for early disease detection and personalized treatment strategies is fueling the demand for glycomics technologies in research and clinical settings.

Second, advancements in drug development, particularly in the field of biologics and monoclonal antibodies, are contributing to the growth of the glycomics market. Many biologic drugs rely on glycosylation for their activity, stability, and safety, and controlling these glycan structures during drug production is essential for creating effective therapies. Pharmaceutical companies are increasingly investing in glycomics tools and technologies to optimize glycosylation in biologics, ensuring that these therapies meet the highest standards for efficacy and safety. This demand for precision in drug development is driving the adoption of glycomics in the pharmaceutical industry.

Third, the growing prevalence of complex diseases, such as cancer, autoimmune disorders, and neurodegenerative diseases, is increasing the need for advanced diagnostic and therapeutic solutions. Glycomics is uniquely positioned to address this need by offering insights into how changes in glycosylation contribute to disease progression. For example, glycan-based biomarkers are being developed for the early detection of cancers, while glycan-targeting therapies are being explored as novel treatments for autoimmune diseases and infectious diseases. As the global burden of these diseases continues to rise, the demand for glycomics-based solutions is expected to grow significantly.

Technological innovations in glycan analysis are also driving the expansion of the glycomics market. Advances in mass spectrometry, glycan arrays, and bioinformatics tools are enabling researchers to analyze glycans with greater speed, accuracy, and resolution. These technologies are making it easier for scientists to map the glycome, identify disease-specific glycan alterations, and develop new glycan-based therapies. The growing availability of high-throughput glycan analysis tools is accelerating research and expanding the commercial potential of glycomics in fields such as diagnostics, therapeutics, and vaccine development.

Additionally, increased funding for glycomics research and the establishment of specialized glycomics research centers are contributing to market growth. Governments, academic institutions, and private companies are investing heavily in glycomics research due to its potential to transform healthcare. Collaborative efforts between academia, industry, and healthcare providers are advancing the application of glycomics in clinical practice, further driving demand for glycomics tools and technologies.

In conclusion, the growth of the glycomics/glycobiology market is being driven by the increasing demand for personalized medicine, advancements in drug development, the growing prevalence of complex diseases, and technological innovations in glycan analysis. As glycomics continues to provide deeper insights into the role of glycans in health and disease, it will play a crucial role in shaping the future of diagnostics, therapeutics, and precision medicine across a wide range of medical and industrial applications.

Select Competitors (Total 152 Featured) -

  • Agilent Technologies, Inc.
  • Bruker Corporation
  • Danaher Corporation
  • Merck KgaA
  • New England Biolabs, Inc.
  • Prozyme, Inc.
  • Shimadzu Corporation
  • Takara Bio, Inc.
  • Thermo Fisher Scientific, Inc.
  • Waters Corporation

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Global Economic Update
    • Glycomics / Glycobiology - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Growing Interest in Glycomics for Understanding Disease Mechanisms Spurs Market Growth
    • Expansion of Glycobiology in Cancer and Immunology Research Drives Demand
    • Role of Glycomics in Developing Targeted Therapies and Personalized Medicine
    • Market Opportunities in Drug Discovery and Development Utilizing Glycomics
    • Role of Glycomics in Vaccine Development and Infectious Disease Research
    • Consumer Demand for Glycan-based Diagnostics and Biomarkers
    • Expansion of Glycomics in Neurological Research and Neurodegenerative Diseases
    • Role of Glycomics in Enhancing Stem Cell and Regenerative Medicine Research
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Glycomics / Glycobiology Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Glycomics / Glycobiology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Glycomics / Glycobiology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 4: World 16-Year Perspective for Glycomics / Glycobiology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2014, 2024 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Enzymes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Enzymes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 7: World 16-Year Perspective for Enzymes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Kits & Reagents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Kits & Reagents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 10: World 16-Year Perspective for Kits & Reagents by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Instruments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Instruments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 13: World 16-Year Perspective for Instruments by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Drug Discovery & Development by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Drug Discovery & Development by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 16: World 16-Year Perspective for Drug Discovery & Development by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 19: World 16-Year Perspective for Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 22: World 16-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Academic & Research Institutes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Academic & Research Institutes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 25: World 16-Year Perspective for Academic & Research Institutes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Pharma & Biotech Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Pharma & Biotech Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 28: World 16-Year Perspective for Pharma & Biotech Companies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Contract Research Organizations by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Contract Research Organizations by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 31: World 16-Year Perspective for Contract Research Organizations by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Glycomics / Glycobiology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 32: USA Recent Past, Current & Future Analysis for Glycomics / Glycobiology by Product - Enzymes, Kits & Reagents and Instruments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 33: USA Historic Review for Glycomics / Glycobiology by Product - Enzymes, Kits & Reagents and Instruments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 34: USA 16-Year Perspective for Glycomics / Glycobiology by Product - Percentage Breakdown of Value Sales for Enzymes, Kits & Reagents and Instruments for the Years 2014, 2024 & 2030
    • TABLE 35: USA Recent Past, Current & Future Analysis for Glycomics / Glycobiology by Application - Drug Discovery & Development, Diagnostics and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 36: USA Historic Review for Glycomics / Glycobiology by Application - Drug Discovery & Development, Diagnostics and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 37: USA 16-Year Perspective for Glycomics / Glycobiology by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development, Diagnostics and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 38: USA Recent Past, Current & Future Analysis for Glycomics / Glycobiology by End-Use - Academic & Research Institutes, Pharma & Biotech Companies and Contract Research Organizations - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 39: USA Historic Review for Glycomics / Glycobiology by End-Use - Academic & Research Institutes, Pharma & Biotech Companies and Contract Research Organizations Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 40: USA 16-Year Perspective for Glycomics / Glycobiology by End-Use - Percentage Breakdown of Value Sales for Academic & Research Institutes, Pharma & Biotech Companies and Contract Research Organizations for the Years 2014, 2024 & 2030
  • CANADA
    • TABLE 41: Canada Recent Past, Current & Future Analysis for Glycomics / Glycobiology by Product - Enzymes, Kits & Reagents and Instruments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 42: Canada Historic Review for Glycomics / Glycobiology by Product - Enzymes, Kits & Reagents and Instruments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 43: Canada 16-Year Perspective for Glycomics / Glycobiology by Product - Percentage Breakdown of Value Sales for Enzymes, Kits & Reagents and Instruments for the Years 2014, 2024 & 2030
    • TABLE 44: Canada Recent Past, Current & Future Analysis for Glycomics / Glycobiology by Application - Drug Discovery & Development, Diagnostics and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 45: Canada Historic Review for Glycomics / Glycobiology by Application - Drug Discovery & Development, Diagnostics and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 46: Canada 16-Year Perspective for Glycomics / Glycobiology by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development, Diagnostics and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 47: Canada Recent Past, Current & Future Analysis for Glycomics / Glycobiology by End-Use - Academic & Research Institutes, Pharma & Biotech Companies and Contract Research Organizations - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 48: Canada Historic Review for Glycomics / Glycobiology by End-Use - Academic & Research Institutes, Pharma & Biotech Companies and Contract Research Organizations Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 49: Canada 16-Year Perspective for Glycomics / Glycobiology by End-Use - Percentage Breakdown of Value Sales for Academic & Research Institutes, Pharma & Biotech Companies and Contract Research Organizations for the Years 2014, 2024 & 2030
  • JAPAN
    • Glycomics / Glycobiology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 50: Japan Recent Past, Current & Future Analysis for Glycomics / Glycobiology by Product - Enzymes, Kits & Reagents and Instruments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 51: Japan Historic Review for Glycomics / Glycobiology by Product - Enzymes, Kits & Reagents and Instruments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 52: Japan 16-Year Perspective for Glycomics / Glycobiology by Product - Percentage Breakdown of Value Sales for Enzymes, Kits & Reagents and Instruments for the Years 2014, 2024 & 2030
    • TABLE 53: Japan Recent Past, Current & Future Analysis for Glycomics / Glycobiology by Application - Drug Discovery & Development, Diagnostics and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 54: Japan Historic Review for Glycomics / Glycobiology by Application - Drug Discovery & Development, Diagnostics and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 55: Japan 16-Year Perspective for Glycomics / Glycobiology by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development, Diagnostics and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 56: Japan Recent Past, Current & Future Analysis for Glycomics / Glycobiology by End-Use - Academic & Research Institutes, Pharma & Biotech Companies and Contract Research Organizations - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 57: Japan Historic Review for Glycomics / Glycobiology by End-Use - Academic & Research Institutes, Pharma & Biotech Companies and Contract Research Organizations Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 58: Japan 16-Year Perspective for Glycomics / Glycobiology by End-Use - Percentage Breakdown of Value Sales for Academic & Research Institutes, Pharma & Biotech Companies and Contract Research Organizations for the Years 2014, 2024 & 2030
  • CHINA
    • Glycomics / Glycobiology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 59: China Recent Past, Current & Future Analysis for Glycomics / Glycobiology by Product - Enzymes, Kits & Reagents and Instruments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 60: China Historic Review for Glycomics / Glycobiology by Product - Enzymes, Kits & Reagents and Instruments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 61: China 16-Year Perspective for Glycomics / Glycobiology by Product - Percentage Breakdown of Value Sales for Enzymes, Kits & Reagents and Instruments for the Years 2014, 2024 & 2030
    • TABLE 62: China Recent Past, Current & Future Analysis for Glycomics / Glycobiology by Application - Drug Discovery & Development, Diagnostics and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 63: China Historic Review for Glycomics / Glycobiology by Application - Drug Discovery & Development, Diagnostics and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 64: China 16-Year Perspective for Glycomics / Glycobiology by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development, Diagnostics and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 65: China Recent Past, Current & Future Analysis for Glycomics / Glycobiology by End-Use - Academic & Research Institutes, Pharma & Biotech Companies and Contract Research Organizations - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 66: China Historic Review for Glycomics / Glycobiology by End-Use - Academic & Research Institutes, Pharma & Biotech Companies and Contract Research Organizations Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 67: China 16-Year Perspective for Glycomics / Glycobiology by End-Use - Percentage Breakdown of Value Sales for Academic & Research Institutes, Pharma & Biotech Companies and Contract Research Organizations for the Years 2014, 2024 & 2030
  • EUROPE
    • Glycomics / Glycobiology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 68: Europe Recent Past, Current & Future Analysis for Glycomics / Glycobiology by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 69: Europe Historic Review for Glycomics / Glycobiology by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 70: Europe 16-Year Perspective for Glycomics / Glycobiology by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2014, 2024 & 2030
    • TABLE 71: Europe Recent Past, Current & Future Analysis for Glycomics / Glycobiology by Product - Enzymes, Kits & Reagents and Instruments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 72: Europe Historic Review for Glycomics / Glycobiology by Product - Enzymes, Kits & Reagents and Instruments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 73: Europe 16-Year Perspective for Glycomics / Glycobiology by Product - Percentage Breakdown of Value Sales for Enzymes, Kits & Reagents and Instruments for the Years 2014, 2024 & 2030
    • TABLE 74: Europe Recent Past, Current & Future Analysis for Glycomics / Glycobiology by Application - Drug Discovery & Development, Diagnostics and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 75: Europe Historic Review for Glycomics / Glycobiology by Application - Drug Discovery & Development, Diagnostics and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 76: Europe 16-Year Perspective for Glycomics / Glycobiology by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development, Diagnostics and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 77: Europe Recent Past, Current & Future Analysis for Glycomics / Glycobiology by End-Use - Academic & Research Institutes, Pharma & Biotech Companies and Contract Research Organizations - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 78: Europe Historic Review for Glycomics / Glycobiology by End-Use - Academic & Research Institutes, Pharma & Biotech Companies and Contract Research Organizations Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 79: Europe 16-Year Perspective for Glycomics / Glycobiology by End-Use - Percentage Breakdown of Value Sales for Academic & Research Institutes, Pharma & Biotech Companies and Contract Research Organizations for the Years 2014, 2024 & 2030
  • FRANCE
    • Glycomics / Glycobiology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 80: France Recent Past, Current & Future Analysis for Glycomics / Glycobiology by Product - Enzymes, Kits & Reagents and Instruments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 81: France Historic Review for Glycomics / Glycobiology by Product - Enzymes, Kits & Reagents and Instruments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 82: France 16-Year Perspective for Glycomics / Glycobiology by Product - Percentage Breakdown of Value Sales for Enzymes, Kits & Reagents and Instruments for the Years 2014, 2024 & 2030
    • TABLE 83: France Recent Past, Current & Future Analysis for Glycomics / Glycobiology by Application - Drug Discovery & Development, Diagnostics and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 84: France Historic Review for Glycomics / Glycobiology by Application - Drug Discovery & Development, Diagnostics and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 85: France 16-Year Perspective for Glycomics / Glycobiology by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development, Diagnostics and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 86: France Recent Past, Current & Future Analysis for Glycomics / Glycobiology by End-Use - Academic & Research Institutes, Pharma & Biotech Companies and Contract Research Organizations - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 87: France Historic Review for Glycomics / Glycobiology by End-Use - Academic & Research Institutes, Pharma & Biotech Companies and Contract Research Organizations Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 88: France 16-Year Perspective for Glycomics / Glycobiology by End-Use - Percentage Breakdown of Value Sales for Academic & Research Institutes, Pharma & Biotech Companies and Contract Research Organizations for the Years 2014, 2024 & 2030
  • GERMANY
    • Glycomics / Glycobiology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 89: Germany Recent Past, Current & Future Analysis for Glycomics / Glycobiology by Product - Enzymes, Kits & Reagents and Instruments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 90: Germany Historic Review for Glycomics / Glycobiology by Product - Enzymes, Kits & Reagents and Instruments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 91: Germany 16-Year Perspective for Glycomics / Glycobiology by Product - Percentage Breakdown of Value Sales for Enzymes, Kits & Reagents and Instruments for the Years 2014, 2024 & 2030
    • TABLE 92: Germany Recent Past, Current & Future Analysis for Glycomics / Glycobiology by Application - Drug Discovery & Development, Diagnostics and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 93: Germany Historic Review for Glycomics / Glycobiology by Application - Drug Discovery & Development, Diagnostics and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 94: Germany 16-Year Perspective for Glycomics / Glycobiology by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development, Diagnostics and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 95: Germany Recent Past, Current & Future Analysis for Glycomics / Glycobiology by End-Use - Academic & Research Institutes, Pharma & Biotech Companies and Contract Research Organizations - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 96: Germany Historic Review for Glycomics / Glycobiology by End-Use - Academic & Research Institutes, Pharma & Biotech Companies and Contract Research Organizations Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 97: Germany 16-Year Perspective for Glycomics / Glycobiology by End-Use - Percentage Breakdown of Value Sales for Academic & Research Institutes, Pharma & Biotech Companies and Contract Research Organizations for the Years 2014, 2024 & 2030
  • ITALY
    • TABLE 98: Italy Recent Past, Current & Future Analysis for Glycomics / Glycobiology by Product - Enzymes, Kits & Reagents and Instruments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 99: Italy Historic Review for Glycomics / Glycobiology by Product - Enzymes, Kits & Reagents and Instruments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 100: Italy 16-Year Perspective for Glycomics / Glycobiology by Product - Percentage Breakdown of Value Sales for Enzymes, Kits & Reagents and Instruments for the Years 2014, 2024 & 2030
    • TABLE 101: Italy Recent Past, Current & Future Analysis for Glycomics / Glycobiology by Application - Drug Discovery & Development, Diagnostics and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 102: Italy Historic Review for Glycomics / Glycobiology by Application - Drug Discovery & Development, Diagnostics and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 103: Italy 16-Year Perspective for Glycomics / Glycobiology by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development, Diagnostics and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 104: Italy Recent Past, Current & Future Analysis for Glycomics / Glycobiology by End-Use - Academic & Research Institutes, Pharma & Biotech Companies and Contract Research Organizations - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 105: Italy Historic Review for Glycomics / Glycobiology by End-Use - Academic & Research Institutes, Pharma & Biotech Companies and Contract Research Organizations Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 106: Italy 16-Year Perspective for Glycomics / Glycobiology by End-Use - Percentage Breakdown of Value Sales for Academic & Research Institutes, Pharma & Biotech Companies and Contract Research Organizations for the Years 2014, 2024 & 2030
  • UNITED KINGDOM
    • Glycomics / Glycobiology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 107: UK Recent Past, Current & Future Analysis for Glycomics / Glycobiology by Product - Enzymes, Kits & Reagents and Instruments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 108: UK Historic Review for Glycomics / Glycobiology by Product - Enzymes, Kits & Reagents and Instruments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 109: UK 16-Year Perspective for Glycomics / Glycobiology by Product - Percentage Breakdown of Value Sales for Enzymes, Kits & Reagents and Instruments for the Years 2014, 2024 & 2030
    • TABLE 110: UK Recent Past, Current & Future Analysis for Glycomics / Glycobiology by Application - Drug Discovery & Development, Diagnostics and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 111: UK Historic Review for Glycomics / Glycobiology by Application - Drug Discovery & Development, Diagnostics and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 112: UK 16-Year Perspective for Glycomics / Glycobiology by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development, Diagnostics and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 113: UK Recent Past, Current & Future Analysis for Glycomics / Glycobiology by End-Use - Academic & Research Institutes, Pharma & Biotech Companies and Contract Research Organizations - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 114: UK Historic Review for Glycomics / Glycobiology by End-Use - Academic & Research Institutes, Pharma & Biotech Companies and Contract Research Organizations Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 115: UK 16-Year Perspective for Glycomics / Glycobiology by End-Use - Percentage Breakdown of Value Sales for Academic & Research Institutes, Pharma & Biotech Companies and Contract Research Organizations for the Years 2014, 2024 & 2030
  • REST OF EUROPE
    • TABLE 116: Rest of Europe Recent Past, Current & Future Analysis for Glycomics / Glycobiology by Product - Enzymes, Kits & Reagents and Instruments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 117: Rest of Europe Historic Review for Glycomics / Glycobiology by Product - Enzymes, Kits & Reagents and Instruments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 118: Rest of Europe 16-Year Perspective for Glycomics / Glycobiology by Product - Percentage Breakdown of Value Sales for Enzymes, Kits & Reagents and Instruments for the Years 2014, 2024 & 2030
    • TABLE 119: Rest of Europe Recent Past, Current & Future Analysis for Glycomics / Glycobiology by Application - Drug Discovery & Development, Diagnostics and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 120: Rest of Europe Historic Review for Glycomics / Glycobiology by Application - Drug Discovery & Development, Diagnostics and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 121: Rest of Europe 16-Year Perspective for Glycomics / Glycobiology by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development, Diagnostics and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 122: Rest of Europe Recent Past, Current & Future Analysis for Glycomics / Glycobiology by End-Use - Academic & Research Institutes, Pharma & Biotech Companies and Contract Research Organizations - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 123: Rest of Europe Historic Review for Glycomics / Glycobiology by End-Use - Academic & Research Institutes, Pharma & Biotech Companies and Contract Research Organizations Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 124: Rest of Europe 16-Year Perspective for Glycomics / Glycobiology by End-Use - Percentage Breakdown of Value Sales for Academic & Research Institutes, Pharma & Biotech Companies and Contract Research Organizations for the Years 2014, 2024 & 2030
  • ASIA-PACIFIC
    • Glycomics / Glycobiology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 125: Asia-Pacific Recent Past, Current & Future Analysis for Glycomics / Glycobiology by Product - Enzymes, Kits & Reagents and Instruments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 126: Asia-Pacific Historic Review for Glycomics / Glycobiology by Product - Enzymes, Kits & Reagents and Instruments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 127: Asia-Pacific 16-Year Perspective for Glycomics / Glycobiology by Product - Percentage Breakdown of Value Sales for Enzymes, Kits & Reagents and Instruments for the Years 2014, 2024 & 2030
    • TABLE 128: Asia-Pacific Recent Past, Current & Future Analysis for Glycomics / Glycobiology by Application - Drug Discovery & Development, Diagnostics and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 129: Asia-Pacific Historic Review for Glycomics / Glycobiology by Application - Drug Discovery & Development, Diagnostics and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 130: Asia-Pacific 16-Year Perspective for Glycomics / Glycobiology by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development, Diagnostics and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 131: Asia-Pacific Recent Past, Current & Future Analysis for Glycomics / Glycobiology by End-Use - Academic & Research Institutes, Pharma & Biotech Companies and Contract Research Organizations - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 132: Asia-Pacific Historic Review for Glycomics / Glycobiology by End-Use - Academic & Research Institutes, Pharma & Biotech Companies and Contract Research Organizations Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 133: Asia-Pacific 16-Year Perspective for Glycomics / Glycobiology by End-Use - Percentage Breakdown of Value Sales for Academic & Research Institutes, Pharma & Biotech Companies and Contract Research Organizations for the Years 2014, 2024 & 2030
  • REST OF WORLD
    • TABLE 134: Rest of World Recent Past, Current & Future Analysis for Glycomics / Glycobiology by Product - Enzymes, Kits & Reagents and Instruments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 135: Rest of World Historic Review for Glycomics / Glycobiology by Product - Enzymes, Kits & Reagents and Instruments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 136: Rest of World 16-Year Perspective for Glycomics / Glycobiology by Product - Percentage Breakdown of Value Sales for Enzymes, Kits & Reagents and Instruments for the Years 2014, 2024 & 2030
    • TABLE 137: Rest of World Recent Past, Current & Future Analysis for Glycomics / Glycobiology by Application - Drug Discovery & Development, Diagnostics and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 138: Rest of World Historic Review for Glycomics / Glycobiology by Application - Drug Discovery & Development, Diagnostics and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 139: Rest of World 16-Year Perspective for Glycomics / Glycobiology by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development, Diagnostics and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 140: Rest of World Recent Past, Current & Future Analysis for Glycomics / Glycobiology by End-Use - Academic & Research Institutes, Pharma & Biotech Companies and Contract Research Organizations - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 141: Rest of World Historic Review for Glycomics / Glycobiology by End-Use - Academic & Research Institutes, Pharma & Biotech Companies and Contract Research Organizations Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 142: Rest of World 16-Year Perspective for Glycomics / Glycobiology by End-Use - Percentage Breakdown of Value Sales for Academic & Research Institutes, Pharma & Biotech Companies and Contract Research Organizations for the Years 2014, 2024 & 2030

IV. COMPETITION